Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA       ES0171996012

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 4 098 M
EBIT 2016 985 M
Net income 2016 553 M
Debt 2016 3 653 M
Yield 2016 1,56%
Sales 2017 4 308 M
EBIT 2017 1 085 M
Net income 2017 639 M
Debt 2017 4 348 M
Yield 2017 1,75%
P/E ratio 2016 26,11
P/E ratio 2017 22,61
EV / Sales2016 4,12x
EV / Sales2017 4,08x
Capitalization 13 239 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
Sector
Pharmaceuticals
Calendar
02/28Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
01/31 GRIFOLS : closes the acquisition of Hologic's share of NAT donor screening unit ..
01/27 TERUMO : Global Medical Blood Transfusion Industry 2017 Market Solutions & Life-..
01/11 GRIFOLS : acuerda con Hologic la compra de su participación en la unidad de diag..
01/10 GRIFOLS : to Acquire Hologic Blood Donor Screening Unit
2016 GRIFOLS : Hologic sells blood-screening business to Grifols for $1.85 million
2016 Spanish shares gain 1.58% to close at 9,331 points
2016 HOLOGIC : sells blood screening unit to Spanish company for $1.8 billion
2016 GRIFOLS : Spain's Grifols plans to refinance debt in first quarter 2017 after Ho..
2016 GRIFOLS : agreed to acquire Hologic’s share of NAT donor screening unit fo..
2016 GRIFOLS : to buy Hologic's stake in blood screening JV for $1.85 billion
More news
Sector news : Biopharmaceuticals
02:02pDJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
12:59a Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
02/23DJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | ES0171996012 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 21,5 €
Spread / Average Target 2,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Director
Víctor Grifols Roura Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Eva Bastida Tubau VP, Director-Scientific & Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA0.00%14 019
BIOGEN INC10.06%61 492
CSL LIMITED20.04%42 089
ALEXION PHARMACEUTICAL..6.93%29 299
BIOMARIN PHARMACEUTICA..7.79%15 357
GRIFOLS SA11.89%14 019
More Results